Saturday 17 October 2026 Export IOVA’s income statement to Excel — free account

Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $263.5 million, up 60.6% from fiscal 2024. In the quarter to June 2026, revenue grew 65.7%, EPS grew 66.7% and free cash flow grew 11.5%, each against the same quarter a year earlier.

13.58 1.14 −7.74%

Follow IOVA

Alert me

Market cap: $6.7B
P/E: 0.0×
Fwd P/E: −7.8×
Dividend yield: —
F-score: 4/9
Altman Z: −2.30
Beneish M: −2.46
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 12.42%

Capital & Financial Ratios $m

Market Cap 6,670.00

Revenue 324.97

Net Income (289.52)

Free Cash Flow (296.39)

Net Debt (297.67)

Current Ratio 4.35

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (7.75)

P/S ratio 18.81

P/B ratio 8.31

Past 5Y EPS Growth —

This Y EPS Growth 59.29%

Next Y EPS Growth 61.46%

Next Y revenue growth 56.62%

Next 5Y EPS Growth 79.45%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/B against its own 10 years 91.82%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	280	324	297	298
Receivables	0	69	82	102
Inventory	10	52	52	56
Other	—	—	—	—
	308	457	443	464

	2023	2024	2025	Q'26
Payables	33	28	22	26
ST’ Debt	—	—	—	—
Other	—	—	—	—
	110	122	138	107

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	—
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	20.98%	1.25%	11.82%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	71	99	—	—	—
’25	49	60	67	87	264
’24	1	31	59	74	164

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(72)	(61)	—	—	—
’25	(104)	(67)	(79)	(53)	(302)
’24	(122)	(98)	(59)	(73)	(353)
’23	(100)	(94)	(84)	(84)	(362)
’22	(74)	(78)	(64)	(78)	(293)
’21	(62)	(54)	(58)	(54)	(228)
’20	(65)	(37)	(41)	(63)	(205)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(79)	(66)	—	—	—
’25	(110)	(75)	(90)	(62)	(336)
’24	(126)	(99)	(61)	(77)	(364)
’23	(105)	(103)	(88)	(87)	(384)
’22	(85)	(82)	(65)	(81)	(313)
’21	(73)	(64)	(67)	(61)	(266)
’20	(66)	(42)	(58)	(86)	(252)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.19)	(0.11)	—	—	—
’25	(0.36)	(0.33)	(0.25)	(0.18)	(1.09)
’24	(0.42)	(0.34)	(0.28)	(0.26)	(1.28)
’23	(0.50)	(0.47)	(0.46)	(0.45)	(1.89)
’22	(0.58)	(0.63)	(0.63)	(0.64)	(2.49)
’21	(0.51)	(0.53)	(0.55)	(0.63)	(2.23)
’20	(0.55)	(0.47)	(0.40)	(0.47)	(1.88)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	4.24	4.45	7.26	8.26	18.70	15.88	5.42	3.21	7.05	1.64	Analyst estimates 2026–2028 Powerpack
	High	9.58	9.54	19.90	29.68	52.43	54.21	19.66	9.36	18.33	8.15
People
People	Employees	51	63	88	148	241	319	503	557	838	975
	Revenue/emp, $m	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.20	0.27
Income, $m
Income, $m	Revenue	—	—	—	—	—	—	—	1	164	264
	Gross margin, %	—	—	—	—	—	—	—	13.12	43.17	34.28
	EBT	(53)	(92)	(124)	(198)	(260)	(342)	(396)	(448)	(375)	(393)
	EBT margin, %	0.00	0.00	0.00	0.00	0.00	0.00	0.00	(37,638.02)	(228.56)	(149.16)
	Net income	(53)	(92)	(124)	(198)	(260)	(342)	(396)	(444)	(372)	(391)
	Depreciation	1	1	0	(2)	3	20	22	30	38	40
Per share, $
Per share, $	Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.01	0.57	0.74
	Earnings	(1.85)	(1.41)	(1.27)	(1.59)	(1.88)	(2.23)	(2.49)	(1.89)	(1.28)	(1.09)
	Cash flow	(0.59)	(1.21)	(1.04)	(1.28)	(1.48)	(1.49)	(1.84)	(1.54)	(1.22)	(0.85)
	Capex	(0.03)	(0.02)	(0.01)	(0.06)	(0.34)	(0.24)	(0.13)	(0.09)	(0.04)	(0.09)
	Free cash flow	(0.62)	(1.22)	(1.05)	(1.33)	(1.82)	(1.73)	(1.97)	(1.63)	(1.26)	(0.94)
	Book value	3.02	2.23	4.79	2.40	4.75	4.05	3.14	2.49	2.45	1.95
	Shares, m	55	65	97	124	138	153	159	235	290	357
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	—	—	0.00	0.00	0.00
	P/S	—	—	—	—	—	—	—	0.00	13.07	3.70
	P/B	—	—	—	—	—	—	—	3.26	3.02	1.40
	EV/Sales	—	—	—	—	—	—	—	0.00	11.11	2.58
	EV/FCF	—	—	—	—	—	—	—	(4.23)	(5.01)	(2.02)
Cash, $m
Cash, $m	Operating cash flow	(33)	(79)	(101)	(159)	(205)	(228)	(293)	(362)	(353)	(302)
	Capex	(2)	(1)	(1)	(7)	(47)	(38)	(20)	(22)	(11)	(34)
	Free cash flow	(34)	(80)	(102)	(166)	(252)	(266)	(313)	(384)	(364)	(336)
Balance, $m
Balance, $m	Working capital	165	140	461	277	581	419	388	198	335	304
	Total debt	—	—	—	4	—	1	1	1	1	—
	Net debt	(166)	(145)	(469)	(303)	(629)	(503)	(471)	(279)	(323)	(297)
	Shareholders’ equity	167	145	466	299	656	622	500	585	710	699
Returns, %
Returns, %	ROA	(73.75)	(56.26)	(38.85)	(47.86)	(46.64)	(44.28)	(54.93)	(61.49)	(44.02)	(42.88)
	ROIC	(7,483.12)	(53,748.26)	0.00	0.00	(604.97)	(181.13)	(865.83)	(94.15)	(63.73)	(62.77)
	ROE	(75.55)	(58.94)	(40.41)	(51.64)	(54.34)	(53.55)	(70.61)	(81.91)	(57.48)	(55.50)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
SYRE Spyre Therapeutics, Inc.	$7.4B	— (loss-making)	— (loss-making)	−100.00% (below 0%: shrinking)	n/m	−50.07% (below 0%: shrinking)	0.00%	0.00%	Compare
IONS Ionis Pharmaceuticals, Inc.	$7.3B	— (loss-making)	— (loss-making)	−40.73% (below 0%: shrinking)	n/m	+299.29% (above 0%: growing)	98.98%	(38.18%)	Compare
PRAX Praxis Precision Medicines, Inc.	$6.9B	— (loss-making)	— (loss-making)	+1,349.13% (above 0%: growing)	n/m	−43.54% (below 0%: shrinking)	100.00%	0.00%	Compare
IOVA Iovance Biotherapeutics, Inc.	$6.7B	— (loss-making)	— (loss-making)	+65.65% (above 0%: growing)	n/m	+11.52% (above 0%: growing)	56.10%	(52.26%)
BLTE Belite Bio, Inc. Sponsored ADR	$6.2B	— (loss-making)	—	—	n/m	+64.67% (above 0%: growing)	—	0.00%	Compare
RYTM Rhythm Pharmaceuticals, Inc.	$6.1B	— (loss-making)	— (loss-making)	+46.91% (above 0%: growing)	n/m	+60.74% (above 0%: growing)	87.47%	(68.14%)	Compare
LGND Ligand Pharmaceuticals Incorporated	$6.0B	29.5×	54.7×	+33.73% (above 0%: growing)	+868.00% (above 0%: growing)	+35.53% (above 0%: growing)	94.95%	13.49%	Compare
IMVT Immunovant, Inc.	$5.7B	— (loss-making)	—	—	n/m	−5.96% (below 0%: shrinking)	0.00%	0.00%	Compare
KOD Kodiak Sciences Inc.	$5.5B	— (loss-making)	—	—	n/m	−33.86% (below 0%: shrinking)	0.00%	0.00%	Compare
Median of peers	$6.1B	—	—	+33.73%	—	+14.79%	87.47%	0.00%

All 614 Biotechnology stocks →

Iovance Biotherapeutics, Inc. (IOVA) key facts

Strength: Iovance Biotherapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $263.5 million, up 60.6% from fiscal 2024.
Iovance Biotherapeutics, Inc. (IOVA) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, IOVA traded at $13.58, a market capitalization of $6.7 billion.
Return on equity was −55.5% and debt-to-equity 0.00.
Its Piotroski F-score is 4 out of 9 and its Altman Z-score is −2.30 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.